rhodamine 123 has been researched along with dexniguldipine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boer, R; Haas, S; Schödl, A | 1 |
| Boer, R; Gekeler, V; Glossmann, H; Gotwald, M; Hofer, S; Hofmann, J; Ise, W; Mitterdorfer, J; Noller, A; Utz, I | 1 |
| Eisterer, W; Hilbe, W; Hofmann, J; Ludescher, C; Thaler, J | 1 |
| Beck, JF; Boer, R; Buchholz, F; Gekeler, V; Niethammer, D; Sanders, KH; Ulrich, WR | 1 |
4 other study(ies) available for rhodamine 123 and dexniguldipine
| Article | Year |
|---|---|
Influence of dexniguldipine-HC1 on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers.
Topics: Antineoplastic Agents; Cyclosporins; Dihydropyridines; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Humans; Hydrogen-Ion Concentration; Leukemia; Rhodamine 123; Rhodamines; Tumor Cells, Cultured | 1994 |
Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance.
Topics: Affinity Labels; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Cell Line; Cell Survival; Dihydropyridines; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Humans; Rhodamine 123; Rhodamines; Transfection; Vincristine | 1995 |
Decreased potency of MDR-modulators under serum conditions determined by a functional assay.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD8-Positive T-Lymphocytes; Cyclosporine; Dihydropyridines; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Rhodamine 123; Rhodamines; Verapamil | 1995 |
Rhodamine 123 efflux modulation in the presence of low or high serum from CD56+ hematopoietic cells or CD34+ leukemic blasts by B9309-068, a newly designed pyridine derivative.
Topics: Acridines; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Blood Proteins; Calcium Channel Blockers; CD56 Antigen; Cyclosporins; Dihydropyridines; Dose-Response Relationship, Drug; Flow Cytometry; Fluorescent Dyes; Gene Expression; Humans; Isoquinolines; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Morpholines; Multidrug Resistance-Associated Proteins; Pyrimidines; Rhodamine 123; Rhodamines; Tetrahydroisoquinolines; Verapamil | 1998 |